StockIQ.techInsmed Incorporated (INSM) Stock Analysis
Free AI-powered analysis and research for Insmed Incorporated stock
Sector: Healthcare
INSM snapshot
Data as of 3 Nov 2026 close. Updated daily.
Insmed Incorporated scores 28/100 on StockIQ's model, which reads as negative signals overall. The price is below its 200-day average and at 13% of its 52-week range, down 43.2% over the past year. Latest reported figures show a profit margin of -39.9%, return on equity of -72.5% and revenue growth of +268.4%.
What is driving the score
- RSI Neutral: +5
- Mixed Trend: +0
- MACD Bullish: +8
- Strong Revenue Growth (268.4%): +8
- Unprofitable (-39.9%): -15
- Strong Liquidity (2.86 Current Ratio): +8
- Negative ROE (-72.5%): -10
- High P/B (34.00): -5
- Long-term Downtrend: -8
- Severe Underperformance (-43.2% over 1 year): -10
- Low Volume (0.5x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full INSM report
Insmed Incorporated (INSM) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze INSM Now →📰 Latest Update
Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats Up
Sat, October 31, 2026 at 4:09 PM UTC 2 min read
Insmed (INSM) raised its guidance following a strong earnings report, indicating improved financial performance and growth prospects. This adjustment is significant for investors as it suggests the company is on a positive trajectory, potentially increasing its market valuation amid ongoing debates about its fair value. The updated outlook may enhance investor confidence and attract new interest in the stock.